Skip to main content

Clinical Trials for Transitional Cell Cancer of the Renal Pelvis and Ureter

Trials 26-32 of 32

Neoadjuvant Immunotherapy (Atezolizumab and Tiragolumab) for the Treatment of Cisplatin-Ineligible Resectable High-Risk, Muscle-Invasive Urothelial Cancer
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
ALG.APV-527 First-in-human Study
Status: Active
Location: Icahn School of Medicine at Mount Sinai, New York, New York
A Personalized Cancer Vaccine for the Treatment of Muscle-Invasive Bladder Cancer and Gastroesophageal Cancer in Patients with Molecular Residual Disease
Status: Active
Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri
Enfortumab Vedotin and Pembrolizumab Followed by Cystectomy and/or Ureterectomy for the Treatment of Locally Advanced or Metastatic Bladder and Upper Urothelial Tract Cancer, CAST-AI Trial
Status: Active
Location: Mayo Clinic in Rochester, Rochester, Minnesota
Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma
Status: Active
Location: 3 locations
A Study of DF6002 Alone and in Combination With Nivolumab
Status: Active
Location: See ClinicalTrials.gov
N-803 in Combination with Pembrolizumab and Enfortumab Vedotin for the Treatment of Locally Advanced and Metastatic Urothelial Cancer
Status: Approved
Location: University of California San Francisco, San Francisco, California